Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds?
For decades, the therapeutic goal of conventional treatment among inflammatory bowel disease (IBD) patients is alleviating exacerbations in acute phase, maintaining remission, reducing recurrence, preventing complications, and increasing quality of life. However, the persistent mucosal/submucosal in...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1298186/full |
| _version_ | 1797391154961973248 |
|---|---|
| author | Min Wang Jingyan Shi Chao Yu Xinyi Zhang Gaoxin Xu Ziyan Xu Yong Ma |
| author_facet | Min Wang Jingyan Shi Chao Yu Xinyi Zhang Gaoxin Xu Ziyan Xu Yong Ma |
| author_sort | Min Wang |
| collection | DOAJ |
| description | For decades, the therapeutic goal of conventional treatment among inflammatory bowel disease (IBD) patients is alleviating exacerbations in acute phase, maintaining remission, reducing recurrence, preventing complications, and increasing quality of life. However, the persistent mucosal/submucosal inflammation tends to cause irreversible changes in the intestinal structure, which can barely be redressed by conventional treatment. In the late 1990s, monoclonal biologics, mainly anti-TNF (tumor necrosis factor) drugs, were proven significantly helpful in inhibiting mucosal inflammation and improving prognosis in clinical trials. Meanwhile, mucosal healing (MH), as a key endoscopic and histological measurement closely associated with the severity of symptoms, has been proposed as primary outcome measures. With deeper comprehension of the mucosal microenvironment, stem cell niche, and underlying mucosal repair mechanisms, diverse potential strategies apart from monoclonal antibodies have been arising or undergoing clinical trials. Herein, we elucidate key steps or targets during the course of MH and review some promising treatment strategies capable of promoting MH in IBD. |
| first_indexed | 2024-03-08T23:28:51Z |
| format | Article |
| id | doaj.art-7e5fdab0a86442da8d02a6b6582a0d76 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T23:28:51Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-7e5fdab0a86442da8d02a6b6582a0d762023-12-14T16:41:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-12-011410.3389/fimmu.2023.12981861298186Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds?Min Wang0Jingyan Shi1Chao Yu2Xinyi Zhang3Gaoxin Xu4Ziyan Xu5Yong Ma6Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaMedical School, Nanjing University, Nanjing, ChinaDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaFor decades, the therapeutic goal of conventional treatment among inflammatory bowel disease (IBD) patients is alleviating exacerbations in acute phase, maintaining remission, reducing recurrence, preventing complications, and increasing quality of life. However, the persistent mucosal/submucosal inflammation tends to cause irreversible changes in the intestinal structure, which can barely be redressed by conventional treatment. In the late 1990s, monoclonal biologics, mainly anti-TNF (tumor necrosis factor) drugs, were proven significantly helpful in inhibiting mucosal inflammation and improving prognosis in clinical trials. Meanwhile, mucosal healing (MH), as a key endoscopic and histological measurement closely associated with the severity of symptoms, has been proposed as primary outcome measures. With deeper comprehension of the mucosal microenvironment, stem cell niche, and underlying mucosal repair mechanisms, diverse potential strategies apart from monoclonal antibodies have been arising or undergoing clinical trials. Herein, we elucidate key steps or targets during the course of MH and review some promising treatment strategies capable of promoting MH in IBD.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1298186/fullinflammatory bowel diseasemucosal healingintestinal mucosal barrieremerging strategyorganoid |
| spellingShingle | Min Wang Jingyan Shi Chao Yu Xinyi Zhang Gaoxin Xu Ziyan Xu Yong Ma Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds? Frontiers in Immunology inflammatory bowel disease mucosal healing intestinal mucosal barrier emerging strategy organoid |
| title | Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds? |
| title_full | Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds? |
| title_fullStr | Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds? |
| title_full_unstemmed | Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds? |
| title_short | Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds? |
| title_sort | emerging strategy towards mucosal healing in inflammatory bowel disease what the future holds |
| topic | inflammatory bowel disease mucosal healing intestinal mucosal barrier emerging strategy organoid |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1298186/full |
| work_keys_str_mv | AT minwang emergingstrategytowardsmucosalhealingininflammatoryboweldiseasewhatthefutureholds AT jingyanshi emergingstrategytowardsmucosalhealingininflammatoryboweldiseasewhatthefutureholds AT chaoyu emergingstrategytowardsmucosalhealingininflammatoryboweldiseasewhatthefutureholds AT xinyizhang emergingstrategytowardsmucosalhealingininflammatoryboweldiseasewhatthefutureholds AT gaoxinxu emergingstrategytowardsmucosalhealingininflammatoryboweldiseasewhatthefutureholds AT ziyanxu emergingstrategytowardsmucosalhealingininflammatoryboweldiseasewhatthefutureholds AT yongma emergingstrategytowardsmucosalhealingininflammatoryboweldiseasewhatthefutureholds |